| Market Cap | 6.05M | P/E | - | EPS this Y | 82.80% | Ern Qtrly Grth | - |
| Income | -45.65M | Forward P/E | -0.47 | EPS next Y | 65.00% | 50D Avg Chg | 133.00% |
| Sales | 7.18M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -72.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | 3.00 | Quick Ratio | 0.14 | Shares Outstanding | 8.79M | 52W Low Chg | 350.00% |
| Insider Own | 4.24% | ROA | -100.17% | Shares Float | 4.66M | Beta | - |
| Inst Own | 49.16% | ROE | - | Shares Shorted/Prior | 374.49K/295.39K | Price | 0.24 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 63,756,935 | Target Price | 3.00 |
| Oper. Margin | -611.35% | Earnings Date | Aug 5 | Volume | 286,459,715 | Change | 54.29% |
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Canaccord Genuity | Hold | Apr 29, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Giffin Brett A. | Chief Commercial Off.. Chief Commercial Officer | Feb 20 | Sell | 0.65 | 537 | 349 | 3,049 | 11/28/23 |
| CR Group L.P. | 10% Owner 10% Owner | Sep 27 | Sell | 0.17 | 13,130,147 | 2,232,125 | 09/29/23 | |
| CR Group L.P. | 10% Owner 10% Owner | Sep 25 | Sell | 0.25 | 250,000 | 62,500 | 5,021,014 | 09/27/23 |
| CR Group L.P. | 10% Owner 10% Owner | Sep 22 | Sell | 0.26 | 5,079,344 | 1,320,629 | 5,088,781 | 09/26/23 |
| CR Group L.P. | 10% Owner 10% Owner | Sep 21 | Sell | 0.3 | 6,338,211 | 1,901,463 | 6,465,629 | 09/25/23 |
| CR Group L.P. | 10% Owner 10% Owner | Sep 20 | Sell | 0.31 | 7,753,710 | 2,403,650 | 8,183,716 | 09/22/23 |
| Gibbs Michael Terrence | General Counsel General Counsel | Mar 28 | Sell | 0.481 | 239 | 115 | 6,612 | 04/06/23 |
| Sperzel John J III | Chairman, CEO, and P.. Chairman, CEO, and President | Apr 07 | Buy | 0.50 | 30,000 | 15,000 | 221,773 | 04/11/22 |
| Barclay Alec | Chief Operations Off.. Chief Operations Officer | Apr 08 | Buy | 0.50 | 12,952 | 6,476 | 181,945 | 04/11/22 |
| Gibbs Michael Terrence | General Counsel General Counsel | Apr 07 | Buy | 0.49 | 10,000 | 4,900 | 166,651 | 04/11/22 |
| Sprague John M | Chief Financial Offi.. Chief Financial Officer | Apr 08 | Buy | 0.4767 | 10,000 | 4,767 | 152,350 | 04/11/22 |
| Giffin Brett A. | Chief Commercial Off.. Chief Commercial Officer | Apr 08 | Buy | 0.489 | 10,600 | 5,183 | 10,600 | 04/11/22 |